Evomela
Total Payments
$400,331
Transactions
277
Doctors
105
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $49,223 | 4 | 1 |
| 2019 | $64,465 | 6 | 3 |
| 2018 | $124,974 | 90 | 45 |
| 2017 | $161,668 | 177 | 67 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $306,124 | 16 | 76.5% |
| Education | $30,891 | 20 | 7.7% |
| Consulting Fee | $25,104 | 12 | 6.3% |
| Honoraria | $17,600 | 5 | 4.4% |
| Travel and Lodging | $14,526 | 52 | 3.6% |
| Food and Beverage | $5,485 | 171 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $600.00 | 1 | 0.1% |
Payments by Type
Research
$306,124
16 transactions
General
$94,206
261 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation | Spectrum Pharmaceuticals Inc. | $60,100 | 0 |
| A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride in Amyloid light-chain AL amyloidosis Patients Undergoing Autologous Stem Cell Transplantation | Aurobindo Pharma USA, Inc. | $58,304 | 0 |
| IIS-MEL-003 | Spectrum Pharmaceuticals Inc. | $50,691 | 0 |
| IIS-MEL-002 | Spectrum Pharmaceuticals Inc. | $50,050 | 0 |
| 04-030# Captisol-Enabled Melphalan Stability Study | Aurobindo Pharma USA, Inc. | $46,548 | 0 |
| Melphalan - General | Spectrum Pharmaceuticals Inc. | $29,985 | 0 |
| A phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCl in combination with Fludarabine and Total Body Irradiation based Reduced Intensity Conditioning for Haploidentical Transplantation | Aurobindo Pharma USA, Inc. | $6,046 | 0 |
| IIS of Evomela | Aurobindo Pharma USA, Inc. | $2,675 | 1 |
| Hamadani-Flu-MEL-TBI | Spectrum Pharmaceuticals Inc. | $1,275 | 0 |
| IIT-HAMADANI-FLU-MEL-TBI | Spectrum Pharmaceuticals Inc. | $450.00 | 0 |
Top Doctors Receiving Payments for Evomela — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Jackson, MS | $39.22 | 1 |
| , M.D | Hematology & Oncology | Nashville, TN | $37.49 | 2 |
| , MD | Hematology | Pittsburgh, PA | $35.89 | 3 |
| , MD | Internal Medicine | Aurora, CO | $33.19 | 1 |
| , DO | Medical Oncology | Robbinsville, NJ | $29.88 | 2 |
| , M.D | Urology | Clifton, NJ | $29.41 | 2 |
| , M.D | Hematology & Oncology | Nashville, TN | $28.61 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | New York, NY | $25.36 | 2 |
| , MD | Hematology | Wilmington, DE | $23.12 | 1 |
| , M.D | Specialist | New York, NY | $23.00 | 1 |
| , MD | Medical Oncology | New Brunswick, NJ | $22.99 | 2 |
| , MD | Hematology & Oncology | Louisville, KY | $22.37 | 2 |
| , M.D. PH.D | Hematology & Oncology | Louisville, KY | $22.37 | 2 |
| , DO | Internal Medicine | Houston, TX | $22.32 | 1 |
| , MD, PHD | Internal Medicine | Baltimore, MD | $22.32 | 1 |
| , M.D | Legal Medicine | Bronx, NY | $22.12 | 2 |
| , D.O | Hematology & Oncology | Pittsburgh, PA | $19.81 | 1 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $19.81 | 1 |
| , M.D | Hematology & Oncology | Atlanta, GA | $19.29 | 1 |
| , MD | Hematology | Wilmington, DE | $19.28 | 1 |
| , M.D | Hematology & Oncology | Tucson, AZ | $19.24 | 1 |
| , M.D | Hematology & Oncology | Tucson, AZ | $19.24 | 1 |
| , D.O | Internal Medicine | La Jolla, CA | $18.03 | 1 |
| , MD | Medical Oncology | Memphis, TN | $17.38 | 1 |
| , M.D | Medical Oncology | Memphis, TN | $17.37 | 1 |
Ad
Manufacturing Companies
- Spectrum Pharmaceuticals Inc. $286,701
- Aurobindo Pharma USA, Inc. $113,630
Product Information
- Type Drug
- Total Payments $400,331
- Total Doctors 105
- Transactions 277
About Evomela
Evomela is a drug associated with $400,331 in payments to 105 healthcare providers, recorded across 277 transactions in the CMS Open Payments database. The primary manufacturer is Spectrum Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $49,223 was paid across 4 transactions to 1 doctors.
The most common payment nature for Evomela is "Unspecified" ($306,124, 76.5% of total).
Evomela is associated with 10 research studies, including "A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation" ($60,100).